Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment

被引:0
|
作者
Li, Shaobo [1 ,2 ]
Zhang, Min [3 ]
Liu, Jin [4 ]
Liu, Shaojun [3 ]
Zhu, Chen [1 ]
Shang, Da [3 ]
Guan, Yi [3 ]
Wang, Qian [1 ]
机构
[1] Fudan Univ, Huashan Hosp, Dept Hematol, Shanghai 200040, Peoples R China
[2] Inner Mongolia Med Univ, Peking Univ Canc Hosp, Dept Nucl Med, Affiliated Canc Hosp, Inner Mongolia Campus, Hohhot 010020, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Nephrol, Shanghai 200040, Peoples R China
[4] Naval Med Univ, Changzheng Hosp, Dept Hematol Myeloma & Lymphoma Ctr, Shanghai 200003, Peoples R China
关键词
Multiple myeloma; Myeloma nephropathy; Renal impairment recovery; Risk nomogram; BORTEZOMIB-BASED CHEMOTHERAPY; CAST NEPHROPATHY; STAGING SYSTEM; HIGH-CUTOFF; FAILURE; HEMODIALYSIS; DISEASE; SAFETY; INDEPENDENCE; MULTICENTER;
D O I
10.1016/j.currproblcancer.2023.100962
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation cohort. The baseline data of the 2 cohorts were compared, and survival and renal recovery rates were analyzed. Independent risk factors affecting renal recovery were determined by binary logistic regression analysis, and a risk nomogram was established and subsequently tested in the external validation cohort. Results: The median overall survival (OS) improved in patients who achieved renal recovery etc within 6 courses of MM directed treatment compared with patients without renal recovery. Median time to renal recovery was 2.65 courses, and the cumulative renal recovery rate during the first 3 courses was 75.05%. Involved serum free light chain (sFLC) ratio of > 120 at diagnosis, time from renal impairment to treatment > 60 days, and a hematologic response without a very good partial remission (VGPR) or better resulted as independent risk factors for renal recovery during the first 3 courses. The established risk nomogram had good discriminative ability and accuracy. Involved sFLC was a key factor affecting renal recovery. Starting treatment as soon as possible after detecting RI and achieving deep hematologic remission during the first 3 courses of treatment helped achieve renal recovery and improve prognosis.(c) 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma
    Utsu, Yoshikazu
    Isono, Yuki
    Masuda, Shin-ichi
    Arai, Hironori
    Shimoji, Sonoko
    Matsumoto, Rena
    Tsushima, Takafumi
    Tanaka, Kazusuke
    Matsuo, Kosuke
    Kimeda, Chiharu
    Konno, Shiho
    Yano, Yudai
    Kuramoto, Nobuhiko
    Aotsuka, Nobuyuki
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 573 - 579
  • [2] The influencing factors of renal response in newly diagnosed multiple myeloma patients with renal impairment
    宋宇航
    ChinaMedicalAbstracts(InternalMedicine), 2023, 40 (02) : 119 - 119
  • [3] A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment
    Liu, Aijun
    Yang, Guangzhong
    Geng, Chuanying
    Wang, Huijuan
    Li, Lihong
    Li, Yanchen
    Wu, Yin
    Tian, Ying
    Leng, Yun
    Wang, Guorong
    Gao, Wen
    Chen, Wenming
    ACTA HAEMATOLOGICA, 2016, 135 (03) : 140 - 145
  • [4] Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
    Jian, Yuan
    Chang, Long
    Shi, Ming-Xia
    Sun, Ying
    Chu, Xiao-Xia
    Xue, Hua
    Huang, Wen-Rong
    Shen, Xu-Liang
    Ma, Jie
    Jia, Guo-Rong
    Feng, Ya-Qing
    Xi, Zhen-Fang
    Zhao, Yan-Hong
    Ma, Yan-Ping
    Xiao, Jing
    Ma, Guang-Yu
    Wang, Qing-Ming
    Bao, Li
    Dong, Yu-Jun
    Zhou, He-Bing
    Sun, Chun-Yan
    Su, Guo-Hong
    Yan, Yan
    Qimuge, Sai-Yin
    Su, Li-Ping
    Sun, Jing-Nan
    Tian, Wei-Wei
    Sun, Xiu-Li
    Ing, Hong-Mei
    Gao, Da
    Chen, Wen-Ming
    Li, Jian
    Gao, Wen
    BLOOD ADVANCES, 2023, 7 (24) : 7581 - 7584
  • [5] Impact of Renal Impairment Criteria on Survival of Patients With Newly Diagnosed Multiple Myeloma
    Strufaldi, Fernando L.
    Segura, Gabriela C.
    Caires, Renato A.
    Mattedi, Francisco Z.
    Costalonga, Elerson
    Martinez, Gracia
    Costa e Silva, Veronica T.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 643 - 643
  • [6] Risk Factors for Renal Failure in Patients with Newly Diagnosed Multiple Myeloma
    Fuentes-Lacouture, Maria C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S28 - S29
  • [7] Prognostic impact of renal failure recovery in patients with newly diagnosed multiple myeloma
    Pena, Camila
    Valladares, Ximena
    Gajardo, Claudia
    Russo, Moises
    Morales, Alvaro
    Correa, Gonzalo
    Valjalo, Ricardo
    REVISTA MEDICA DE CHILE, 2019, 147 (11) : 1374 - 1381
  • [8] PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA PRESENTING WITH RENAL IMPAIRMENT
    Kim, H. J.
    Yang, D. H.
    Ahn, J. S.
    Jung, S. H.
    Kim, Y. K.
    Lee, J. J.
    HAEMATOLOGICA, 2014, 99 : 640 - 640
  • [9] The Reversal of Renal Impairment and its Impact on Survival in Newly Diagnosed Multiple Myeloma Patients
    Gonsalves, Wilson I.
    Leung, Nelson
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Buadi, Francis K.
    Lacy, Martha Q.
    Dingli, David
    Kapoor, Prashant
    Lust, John A.
    Go, Ronald S.
    Hayman, Suzanne R.
    Lin, Yi
    Zeldenrust, Steven
    Kyle, Robert A.
    Gertz, Morie A.
    Kumar, Shaji K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S239 - S239
  • [10] Effects of bortezomib on the prognosis of the newly-diagnosed multiple myeloma patients with renal impairment
    Yang, Guangzhong
    Wang, Jing
    Fu, Lina
    Shen, Man
    Jiang, Luan
    Zhang, Yong
    Huang, Zhongxia
    Gao, Wen
    Zhang, Lei
    Wu, Yin
    Li, Lihong
    Chen, Wenming
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2012, 6 (11): : 793 - 797